Dr. Bin Shao 邵彬
Chief Physician, Associate Professor
Department of Medical Oncology for Breast Cancer, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and medical treatment of breast cancer, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Focuses on recurrent and metastatic cases involving the liver, bone, lung, brain, chest wall, pleural effusion, and ascites, as well as triple-negative, HER2-positive, drug-resistant, and refractory breast cancer.
Dr. Shao holds a PhD from Peking University Health Science Center and specializes in medical oncology for breast cancer. In 2007, Dr. Shao worked for one year at M.D. Anderson Cancer Center. Dr. Shao participates in multiple international multicenter clinical trials and focuses on precision targeted therapy, immunotherapy, and managing drug-resistant or difficult metastatic cases.
Name order: in Chinese the family name comes first (Shao Bin). Papers usually list the name as Bin Shao or Shao B.
Selected publications
56 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2024 (first author): Metastatic breast cancer with double heterozygosity for the BRCA1 and BRCA2 genes responding to olaparib: A case report. PubMed 38646498
- Ann Transl Med, 2023 (first author): The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. PubMed 36819544
- Curr Oncol, 2022 (first author): Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. PubMed 36135052
- Ann Transl Med, 2022 (first author): The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(-) metastatic breast cancer: a retrospective study. PubMed 36111005
- Technol Cancer Res Treat, 2019 (first author): Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. PubMed 30786836
- J BUON, 2018 (first author): Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study. PubMed 30610781
- Am J Cancer Res, 2018 (first author): Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. PubMed 30323975
- Int J Clin Exp Pathol, 2018 (first author): Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. PubMed 31938151
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion